Core Viewpoint - Beixin Life Technology Co., Ltd. has successfully listed on the STAR Market, marking a significant milestone as the first medical device company in the cardiovascular field to do so since 2024, breaking the long-standing monopoly of foreign giants in the high-end interventional medical device sector [1] Group 1: Market Opportunity and Product Innovation - Cardiovascular diseases are a leading health threat globally, with 330 million patients in China, including approximately 11.39 million with coronary heart disease, indicating a rising prevalence [2] - The company focuses on addressing critical clinical pain points in cardiovascular diagnosis and treatment, having developed innovative solutions such as the Intravascular Ultrasound (IVUS) and Fractional Flow Reserve (FFR) systems, which enhance the precision of coronary interventions [2][3] - The IVUS system is the first domestically approved high-definition product, while the FFR system is recognized as a "gold standard" for coronary heart disease diagnosis, significantly reducing patient burden and improving treatment accuracy [3] Group 2: Research and Development Strength - The company has invested 438 million yuan in R&D from 2022 to June 2025, with a projected R&D expense ratio of 35.65% in 2024, surpassing industry averages [4] - Beixin Life has secured 185 domestic and international patents, including 86 invention patents, covering key technologies in ultrasound transducers and image algorithms [4] Group 3: Product Portfolio and Market Penetration - The company has developed a comprehensive product ecosystem covering diagnostic devices, therapeutic instruments, and supporting consumables, enhancing procurement stickiness for hospitals [5] - As of September 2025, Beixin Life's products are available in 30 provinces and approximately 1,000 hospitals in China, with over 70% being tertiary hospitals [7] Group 4: Financial Performance and Growth - The company's revenue surged from 92.45 million yuan in 2022 to 317 million yuan in 2024, representing a growth of over 340%, with a year-on-year increase of 71.29% in 2024 [7] - Despite price pressures from centralized procurement, the company maintained a gross margin of 63.32% in 2024, demonstrating resilience and effective cost control [10] Group 5: Industry Trends and Future Outlook - The cardiovascular interventional device market is projected to grow significantly, driven by an aging population and supportive policies, with the precision PCI market expected to expand from 2.04 billion yuan in 2022 to 9.42 billion yuan by 2030, at a CAGR of approximately 21.1% [11] - The penetration rates for FFR and IVUS in China are currently low, at 3.4% and under 5% respectively, indicating substantial growth potential as clinical awareness increases and domestic product prices decrease [13] - Beixin Life aims to leverage its first-mover advantage in the domestic market and its CE MDR certification to capture a larger share of the global cardiovascular interventional device market [17][19]

Core Viewpoint - Beixin Life (688712.SH) has launched its subscription with an issue price of 17.52 yuan per share, aiming to innovate in cardiovascular disease diagnosis and treatment through advanced medical devices [1] Company Overview - Beixin Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] - The company plans to launch a total of 11 products by September 30, 2025, with 6 products currently under development, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [1] Key Products - The core product, the IVUS system, is China's first domestically developed 60MHz high-definition and high-speed IVUS product, designed to efficiently guide precise PCI strategy formulation [1] - The FFR measurement system is the first domestically approved product in China within the gold standard FFR field, both products are undergoing special review procedures for innovative medical devices [1] Market Position - After launching, the core products quickly captured the second-largest market share domestically and the largest share among domestic brands, contributing to the increase in the localization rate of high-end active interventional medical devices [1] Financial Performance - Revenue for the years 2022, 2023, 2024, and the first half of 2025 is approximately 92.45 million yuan, 184 million yuan, 317 million yuan, and 259 million yuan respectively, with net profits of -30 million yuan, -15.55 million yuan, -5.37 million yuan, and 4.55 million yuan [2] - As of June 30, 2025, total assets are approximately 838.54 million yuan, with equity attributable to the parent company at 755.23 million yuan and a debt-to-asset ratio of 15.20% [3]

深圳北芯生命科技股份有限公司 首次公开发行股票并在科创板上市 招股意向书附件 2026 年 1 月 | 序号 | 文件名称 | 页码 | | --- | --- | --- | | 1 | 发行保荐书 | 1 | | 2 | 财务报表及审计报告 | 51 | | 3 | 审阅报告 | 257 | | 4 | 内部控制审计报告 | 391 | | 5 | 经注册会计师鉴证的非经常性损益明细表 | 416 | | 6 | 法律意见书 | 427 | | 7 | 律师工作报告 | 956 | | 8 | 发行人公司章程（草案） | 1109 | | 9 | 中国证监会同意本次发行注册的文件 | 1155 | 关于深圳北芯生命科技股份有限公司 首次公开发行股票并在科创板上市的发行保荐书 中国国际金融股份有限公司 关于深圳北芯生命科技股份有限公司 首次公开发行股票并在科创板上市的 中国证券监督管理委员会、上海证券交易所： 发行保荐书 保荐人 （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 深圳北芯生命科技股份有限公司（以下简称"北芯生命"、"发行人"或 "公司"）拟申请首次公开发行股票并在科 ...

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has passed the IPO review by the Shanghai Stock Exchange, marking it as the 34th company to receive approval this year [1] Company Overview - Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, with a commitment to developing transformative solutions [1] - The company has launched 11 products to date and has 6 products under development, covering five major categories: IVUS systems, FFR systems, vascular access products, shockwave balloon therapy systems, and electrophysiological solutions [1] Shareholding Structure - The company has no controlling shareholder, with the actual controller being Song Liang, who holds 16.1530% of the shares directly and controls an additional 13.4140% through partnerships, totaling 29.5670% of voting rights [2] - Other shareholders are primarily financial investors who have committed not to seek control of the company, recognizing Song Liang's position as the actual controller [2] Management and Governance - Song Liang is the core founder and has served as the chairman and CEO, significantly influencing the selection of board members and daily management decisions [3] - The company plans to publicly issue up to 90 million shares on the Sci-Tech Innovation Board, with a minimum of 10% of the total share capital post-issue [3] Fundraising Plans - Beixin Life aims to raise approximately 95.22113 million yuan, which will be allocated to the construction of a medical device industrialization base, R&D projects, and to supplement working capital [3] Market Position and Competitive Landscape - The IPO review committee raised questions regarding the market space, competitive landscape, and sustainability of the company's core products, specifically FFR and IVUS [4]